A Study to Evaluate Efficacy and Safety of HCP1803 Compared to RLD2001-1 in Patients with Essential Hypertension
NCT06438172
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
249
Enrollment
INDUSTRY
Sponsor class
Conditions
Hypertension
Interventions
DRUG:
HCP1803-3
DRUG:
RLD2001-1
DRUG:
HPP2003-3
DRUG:
HPP2002-1
Sponsor
Hanmi Pharmaceutical Company Limited